13.03.2018 – 17:59

BB Biotech AG

DGAP-News: BB BIOTECH AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.30

DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM
BB BIOTECH AG: Shareholders at the general meeting vote in favor of all
proposals and approve the dividend of CHF 3.30

13.03.2018 / 17:40
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Media Release of March 13, 2018
 

BB Biotech AG: Shareholders at the general meeting vote in favor of all
proposals and approve the dividend of CHF 3.30
 

All proposals of BB Biotech AG's Board of Directors were approved by its
shareholders at the Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.30
per share. Payment will be made on March 19, 2018, the date of record is March
16, 2018 and the ex-dividend date is March 15, 2018.

Shareholders elected the previous board members Dr. Erich Hunziker, Chairman,
Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another one-year term of
office.

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Dr. Silvia Schanz,ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio,mga@bellevue.ch
Claude Mikkelsen,cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Tanja Chicherio,tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, Tel. +41
79 423 22 28
Thomas Egger,  teg@te-communications.ch
www.bbbiotech.com
 

Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.

Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements included
in this release are made only as of the date of this release and BB Biotech and
its directors and officers assume no obligation to update any forward-looking
statements as a result of new information, future events or other factors.

--------------------------------------------------------------------------------
13.03.2018  Dissemination of a Corporate News, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------------

Language: English

Company:  BB BIOTECH AG

          Schwertstrasse 6

          8200 Schaffhausen

          Switzerland

Phone:    +41 52 624 08 45

E-mail:    info@bbbiotech.com

Internet: www.bbbiotech.ch

ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX



 

End of News DGAP News Service

--------------------------------------------------------------------------------

663703  13.03.2018